| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/25/2011 | EP2324827A1 Therapeutic agent for anca-related vasculitis |
| 05/25/2011 | EP2324826A1 Hydrophilic amino acid-containing preparation having improved taste |
| 05/25/2011 | EP2324825A1 Aryl ureas with angiogenesis inhibiting activity |
| 05/25/2011 | EP2324824A2 Medical application of lipid derivatives of dopamine |
| 05/25/2011 | EP2324823A2 Retinoid replacements and opsin agonists and methods for the use thereof |
| 05/25/2011 | EP2324820A1 Stable Fluindione composition comprising one or more antioxidant agents |
| 05/25/2011 | EP2324812A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 05/25/2011 | EP2324356A1 Compositions and methods affecting the signaling pathways of lrp receptors |
| 05/25/2011 | EP2324065A1 A heparan sulphate which binds bmp2 |
| 05/25/2011 | EP2324046A2 Tgr5 modulators and methods of use thereof |
| 05/25/2011 | EP2324043A1 Nucleoside derivatives as inhibitors of viral polymerases |
| 05/25/2011 | EP2324042A1 Process for preparing azacytidine intermediate |
| 05/25/2011 | EP2324041A2 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| 05/25/2011 | EP2324040A1 Novel polymorphic form of chdmapp, method of preparation thereof, and pharmaceutical composition comprising same |
| 05/25/2011 | EP2324036A1 Bicyclic heterocycle derivatives and methods of use thereof |
| 05/25/2011 | EP2324035A1 Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
| 05/25/2011 | EP2324033A1 Isosorbide nitrates having vasodilating activity |
| 05/25/2011 | EP2324032A2 Inhibitors of beta-secretase |
| 05/25/2011 | EP2324031A1 Nitrogenated derivatives of pancratistatin |
| 05/25/2011 | EP2324029A2 Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 05/25/2011 | EP2324028A2 Therapeutic agents 414 |
| 05/25/2011 | EP2324026A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 05/25/2011 | EP2324025A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 05/25/2011 | EP2324024A1 Diazacarbazoles and methods of use |
| 05/25/2011 | EP2324023A1 Vigor enhancement via administration of pyrimidine derivatives |
| 05/25/2011 | EP2324022A1 Substituted naphthyridines and use thereof as medicines |
| 05/25/2011 | EP2324021A1 Diazaindole derivatives and their use in the inhibition of c-jun n-terminal kinase |
| 05/25/2011 | EP2324020A2 Piperidine derivatives as jak3 inhibitors |
| 05/25/2011 | EP2324019A1 A crystalline form of 4-(5-{(ir)-1-[5- (3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl) pyridine |
| 05/25/2011 | EP2324018A1 Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
| 05/25/2011 | EP2324017A2 INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
| 05/25/2011 | EP2324016A1 3-(n-heterocyclyl)-pyrrolidinyl-phenyl-oxazolidinones as antibacterial agents |
| 05/25/2011 | EP2324015A2 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 05/25/2011 | EP2324014A2 Silent desensitizers of neuronal nachr and methods of use thereof |
| 05/25/2011 | EP2324013A1 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| 05/25/2011 | EP2324012A1 New compounds |
| 05/25/2011 | EP2324008A1 3,4-diarylpyrazoles as protein kinase inhibitors |
| 05/25/2011 | EP2324007A1 Triazole derivatives and their use as nicotinic acetylcholine receptor modulators |
| 05/25/2011 | EP2324006A2 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| 05/25/2011 | EP2324005A1 Novel methylenedioxy phenolic compounds and their use to treat disease |
| 05/25/2011 | EP2324003A1 6-substituted isoflavonoid compounds and uses thereof |
| 05/25/2011 | EP2324002A2 Processes for the preparation of sglt2 inhibitors |
| 05/25/2011 | EP2323998A1 Aryl-sulphonamidic dimers as metalloproteases inhibitors |
| 05/25/2011 | EP2323993A2 2,6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
| 05/25/2011 | EP2323992A1 5-alkynyl-pyrimidines |
| 05/25/2011 | EP2323991A2 Chymase inhibitors |
| 05/25/2011 | EP2323988A1 Alpha7 nicotinic acetylcholine receptor inhibitors |
| 05/25/2011 | EP2323986A2 Hetoerocyclyl carbonic acid amides as antiproliferative agents, pdkl inhibitors |
| 05/25/2011 | EP2323985A1 Tripyridyl carboxamide orexin receptor antagonists |
| 05/25/2011 | EP2323984A1 Two phase bioactive formulations |
| 05/25/2011 | EP2323983A1 Piperidinyl derivative as a modulator of chemokine receptor activity |
| 05/25/2011 | EP2323982A1 Fluorescent regulators of rassf1a expression and human cancer cell proliferation |
| 05/25/2011 | EP2323980A1 7-(piperazine-1-ymethyl)-1h-indole-2-carboxylic acid (phenyl)-amide derivatives and allied compounds as p38 map kinase inhibitors for the treatment of respiratory diseases |
| 05/25/2011 | EP2323977A1 Atorvastatin-aliskiren |
| 05/25/2011 | EP2323971A1 Salicylamide derivatives as nicotinic alpha 7 modulators |
| 05/25/2011 | EP2323970A1 Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists |
| 05/25/2011 | EP2323967A2 Fesoterodine comprising a reduced amount of dehydroxyfesoterodine |
| 05/25/2011 | EP2323737A2 Triazole compounds that modulate hsp90 activity |
| 05/25/2011 | EP2323736A1 Treatment of fibrotic eye disorders using an mmp2 inhibitor |
| 05/25/2011 | EP2323735A1 Substituted pyridoxine-lactam carboxylate salts |
| 05/25/2011 | EP2323734A1 Cyclopropylchromene derivatives as modulators of the alpha-2c receptor |
| 05/25/2011 | EP2323693A1 Drug carriers |
| 05/25/2011 | EP2323690A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
| 05/25/2011 | EP2323689A1 Treatment and/or prevention of peanut induced anaphylaxis |
| 05/25/2011 | EP2323684A2 Use of a pneumococcal p4 peptide for enhancing opsonophagocytosis in response to a pathogen |
| 05/25/2011 | EP2323673A1 Antimicrobial silver solutions |
| 05/25/2011 | EP2323671A1 Aabb-poly(depsipeptide) biodegradable polymers and methods of use |
| 05/25/2011 | EP2323670A1 Polyurethane-grafted hydrogels |
| 05/25/2011 | EP2323669A1 Arabinoxylans for modulating the barrier function of the intestinal surface |
| 05/25/2011 | EP2323668A1 Use of d-ribose for fatigued subjects |
| 05/25/2011 | EP2323667A1 Modulation of transthyretin expression for the treatment of cns related disorders |
| 05/25/2011 | EP2323666A1 Pharmaceutical uses of lanosta-8,24-dien-3-ols |
| 05/25/2011 | EP2323665A1 Fused heterocyclic compounds useful as kinase modulators |
| 05/25/2011 | EP2323664A1 Use of a cdk inhibitor for the treatment of glioma |
| 05/25/2011 | EP2323663A1 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines |
| 05/25/2011 | EP2323662A1 Treating inflammation and related conditions with irindalone |
| 05/25/2011 | EP2323661A1 A3 adenosine receptor allosteric modulators |
| 05/25/2011 | EP2323660A2 Small molecule inhibitors of retroviral assembly and maturation |
| 05/25/2011 | EP2323659A1 Compounds useful as inhibitors of protein kinases |
| 05/25/2011 | EP2323658A1 A new crystalline form of 4-(5-{ (ir)-1-[5-(3- chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-l, 2, 4-triazol-3-yl) pyridine |
| 05/25/2011 | EP2323657A1 Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye |
| 05/25/2011 | EP2323656A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist |
| 05/25/2011 | EP2323655A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient |
| 05/25/2011 | EP2323654A1 Polymorphic form of granisetron hydrochloride and methods of making the same |
| 05/25/2011 | EP2323653A1 2-hydroxy-ethanesulfonate salt |
| 05/25/2011 | EP2323652A2 Treatment of lysosomal storage disorders and other proteostatic diseases |
| 05/25/2011 | EP2323651A2 Compounds for the treatment of flaviviral infections |
| 05/25/2011 | EP2323650A1 Treatment for diabetes in patients inappropriate for metformin therapy |
| 05/25/2011 | EP2323649A2 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |
| 05/25/2011 | EP2323648A2 Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre |
| 05/25/2011 | EP2323647A1 Long-term treatment of symptomatic heart failure |
| 05/25/2011 | EP2323646A1 Use of steroid sulfatase inhibitors for the treatment of preterm labor |
| 05/25/2011 | EP2323645A1 Use of low-dose local anaesthetic or derivatives thereof for therapy of chronic pain, especially migraine |
| 05/25/2011 | EP2323644A2 N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation |
| 05/25/2011 | EP2323643A1 Composition and method for treatment of mrsa |
| 05/25/2011 | EP2323642A1 Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders |
| 05/25/2011 | EP2323641A2 Nyasol and analogs thereof for the treatment of estrogen receptor beta-mediated diseases |
| 05/25/2011 | EP2323640A2 Methods and compositions for treating neuronal damage and modulating transient receptor potential channels |
| 05/25/2011 | EP2323639A1 Emollient composition |
| 05/25/2011 | EP2323638A1 Compositions and methods for treating osteoarthritis |